Scarica l'app Stockscreener
376.04
1.22%
4.54
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$371.50
Aprire:
$372.725
Volume 24 ore:
2.45M
Relative Volume:
0.94
Capitalizzazione di mercato:
$202.95B
Reddito:
$37.30B
Utile/perdita netta:
$7.80B
Rapporto P/E:
26.15
EPS:
14.3793
Flusso di cassa netto:
$8.60B
1 W Prestazione:
+2.66%
1M Prestazione:
+7.00%
6M Prestazione:
+9.08%
1 anno Prestazione:
+21.87%
Intervallo 1D:
$372.16
$379.41
Intervallo di 1 settimana:
$359.21
$379.41
Portata 52W:
$269.77
$391.29
Amgen Inc Stock (AMGN) Company Profile
Nome
Amgen Inc
Settore
Industria
Telefono
(805)447-1000
Indirizzo
ONE AMGEN CENTER DRIVE, THOUSAND OAKS, CA
Compare AMGN vs LLY, JNJ, ABBV, MRK, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMGN
Amgen Inc
|
376.04 | 202.95B | 37.30B | 7.80B | 8.60B | 14.38 |
LLY
Lilly Eli Co
|
1,196.03 | 1.07T | 72.25B | 25.28B | 10.37B | 27.78 |
JNJ
Johnson Johnson
|
263.40 | 634.77B | 97.93B | 21.04B | 17.80B | 8.6278 |
ABBV
Abbvie Inc
|
259.36 | 458.24B | 62.82B | 3.60B | 19.98B | 2.0274 |
MRK
Merck Co Inc
|
131.07 | 323.72B | 65.51B | 8.93B | 14.12B | 3.5532 |
NVS
Novartis Ag Adr
|
155.01 | 294.63B | 54.66B | 13.58B | 16.05B | 7.0171 |
Amgen Inc Stock (AMGN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-04-21 | Iniziato | Canaccord Genuity | Hold |
| 2026-03-10 | Iniziato | Jefferies | Hold |
| 2026-02-20 | Iniziato | Barclays | Equal Weight |
| 2026-01-20 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2026-01-07 | Ripresa | UBS | Buy |
| 2025-12-05 | Aggiornamento | Erste Group | Hold → Buy |
| 2025-11-24 | Ripresa | Truist | Hold |
| 2025-11-13 | Iniziato | Scotiabank | Sector Outperform |
| 2025-09-03 | Ripresa | Raymond James | Mkt Perform |
| 2025-05-20 | Ripresa | Guggenheim | Neutral |
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Neutral |
| 2024-12-10 | Ripresa | BofA Securities | Underperform |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-14 | Iniziato | Citigroup | Neutral |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-14 | Downgrade | Truist | Buy → Hold |
| 2024-09-27 | Iniziato | Cantor Fitzgerald | Overweight |
| 2024-08-07 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2024-05-03 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2024-05-03 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2024-03-28 | Ripresa | Raymond James | Mkt Perform |
| 2024-02-07 | Downgrade | Leerink Partners | Outperform → Market Perform |
| 2023-12-21 | Aggiornamento | Daiwa Securities | Neutral → Buy |
| 2023-12-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-12-12 | Aggiornamento | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Aggiornamento | Truist | Hold → Buy |
| 2023-10-20 | Ripresa | JP Morgan | Neutral |
| 2023-10-17 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-10-11 | Ripresa | BofA Securities | Neutral |
| 2023-09-06 | Iniziato | HSBC Securities | Buy |
| 2023-04-24 | Reiterato | Oppenheimer | Outperform |
| 2023-03-13 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-02-13 | Reiterato | Truist | Buy |
| 2022-11-18 | Iniziato | Credit Suisse | Underperform |
| 2022-10-31 | Downgrade | Barclays | Equal Weight → Underweight |
| 2022-10-11 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-09 | Reiterato | Barclays | Equal Weight |
| 2022-02-09 | Reiterato | Jefferies | Buy |
| 2022-02-09 | Reiterato | Morgan Stanley | Equal-Weight |
| 2022-02-09 | Reiterato | Oppenheimer | Outperform |
| 2022-02-09 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-05 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Buy |
| 2021-11-19 | Iniziato | BMO Capital Markets | Market Perform |
| 2021-09-23 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2021-09-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-12-29 | Iniziato | Daiwa Securities | Buy |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-10-26 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-10-12 | Aggiornamento | Truist | Hold → Buy |
| 2020-10-09 | Downgrade | Bernstein | Outperform → Mkt Perform |
| 2020-10-09 | Downgrade | Truist | Buy → Hold |
| 2020-10-08 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-04-15 | Ripresa | Guggenheim | Neutral |
| 2020-03-31 | Iniziato | Wolfe Research | Peer Perform |
| 2020-03-30 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2020-03-05 | Aggiornamento | BofA/Merrill | Neutral → Buy |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-31 | Downgrade | Robert W. Baird | Neutral → Underperform |
| 2020-01-21 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2019-12-24 | Iniziato | Raymond James | Mkt Perform |
| 2019-12-17 | Ripresa | Morgan Stanley | Overweight |
| 2019-11-12 | Iniziato | SunTrust | Buy |
| 2019-11-05 | Aggiornamento | Cantor Fitzgerald | Neutral → Overweight |
| 2019-10-17 | Ripresa | BofA/Merrill | Neutral |
| 2019-08-19 | Downgrade | Mizuho | Buy → Neutral |
| 2019-05-23 | Aggiornamento | Citigroup | Neutral → Buy |
Mostra tutto
Amgen Inc Borsa (AMGN) Ultime notizie
Aristotle Capital Management LLC Lowers Stock Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen stock edges higher as KRAS lung cancer data and revenue growth support outlook - AD HOC NEWS
Amgen stock trades steadily as recent earnings and obesity drug pipeline shape outlook - AD HOC NEWS
Amgen submits new data to challenge FDA's proposal to withdraw Tavneos - Reuters
Amgen stock trades steady as oncology and cardiovascular drugs support outlook - AD HOC NEWS
Amgen Inc. Revenue Breakdown – HAN:AMG - TradingView
Amgen hands in data package in hopes of FDA hearing for Tavneos defense - Fierce Pharma
Amgen stock trades steady as recent earnings and pipeline updates shape investor focus - AD HOC NEWS
Amgen Says Strongly Disagrees With FDA'S Proposal To Withdraw Tavneos From The U.S. Market - TradingView
Amgen Inc. $AMGN Shares Sold by Oak Associates Ltd. OH - MarketBeat
Public Employees Retirement System of Ohio Grows Position in Amgen Inc. $AMGN - MarketBeat
Amgen Inc. $AMGN Shares Bought by Sei Investments Co. - MarketBeat
Compound Planning Inc. Buys 7,818 Shares of Amgen Inc. $AMGN - MarketBeat
Dickmeyer Boyce Financial Management Inc. Acquires Shares of 2,888 Amgen Inc. $AMGN - MarketBeat
Amgen stock trades steady as biosimilar growth offsets mixed Q1 2026 trends - AD HOC NEWS
Amgen Inc. $AMGN Shares Acquired by Cetera Investment Advisers - MarketBeat
Bank of Nova Scotia Has $110.56 Million Stock Position in Amgen Inc. $AMGN - MarketBeat
Amgen stock trades steady as recent earnings and pipeline progress shape investor view - AD HOC NEWS
Therapeutics Stocks Q1 Teardown: Amgen (NASDAQ:AMGN) Vs The Rest - Yahoo Finance
What Amgen (AMGN)'s Blocked Colorado Enbrel Price Cap Means For Shareholders - simplywall.st
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts - Yahoo Finance Singapore
Amgen Inc. stock outperforms competitors on strong trading day - MarketWatch
iShares Global Healthcare ETF vs VanEck Biotech ETF: Which ETF Is Better for Profiting With Healthcare in 2026? - The Motley Fool
Amgen stock rises on earnings and pipeline progress - Ad-hoc-news.de
Amgen Inc (NASDAQ:AMGN) Shows Technical Strength and Breakout Setup - ChartMill
Amgen stock edges higher as oncology pipeline and restructuring savings shape outlook - Ad-hoc-news.de
Amgen Inc. $AMGN Shares Acquired by NewEdge Wealth LLC - MarketBeat
Amgen Inc. $AMGN Shares Bought by First Trust Advisors LP - MarketBeat
Amgen Inc (AMGN) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Amgen stock holds near record levels as earnings and guidance frame the outlook - Ad-hoc-news.de
AMGN stock rises as 2025 revenue reaches $33.4 billion - Ad-hoc-news.de
Composition or Method? How Amgen and Teva Are Reshaping Drug Patent Strategy - JD Supra
Amgen stock trades steady as oncology and obesity pipeline shapes long term growth - Ad-hoc-news.de
Amgen (AMGN) Settles Lawsuit for $74 Million Over Tax Disclosure Delay - GuruFocus
Working capital per share of Amgen Inc. – BCS:AMGN1 - TradingView
Amgen stock trades steadily as recent results and pipeline shape investor sentiment - Ad-hoc-news.de
PNC Financial Services Group Inc. Buys 24,577 Shares of Amgen Inc. $AMGN - MarketBeat
Danica Pension Livsforsikringsaktieselskab Invests $12.14 Million in Amgen Inc. $AMGN - MarketBeat
ABN Amro Investment Solutions Cuts Holdings in Amgen Inc. $AMGN - MarketBeat
Amgen stock holds steady as Repatha growth offsets biosimilar pressure - Ad-hoc-news.de
Amgen (AMGN) Clears An Enbrel Overhang, Is The Stock Fully Priced? - Yahoo! Finance Canada
Amgen (AMGN) Stock Looks Reasonable On Earnings While Cash Flow Stays Strong - simplywall.st
ETFs Investing in Amgen Inc. Stocks - TradingView
More Than Dry Eyes: The Many Faces of Sjögren’s Disease - Amgen
Amgen To Pay $74M To End Investor Suit Over $10.7B Tax Bill - Law360
$100 Invested In Amgen 15 Years Ago Would Be Worth This Much Today - Benzinga
Amgen agrees to $74M settlement to resolve investor lawsuit over potential $10.7B tax bill - Fierce Pharma
Amgen Settles Investor Suit Over Tax Liability for $74 Million - Bloomberg Law News
Amgen stock trades steady as obesity pipeline and recent earnings shape outlook - Ad-hoc-news.de
Amgen settles shareholder lawsuit claiming it hid $10.7 billion tax bill - Reuters
Amgen stock holds near its yearly range as investors await the next earnings date. - Ad-hoc-news.de
Amgen Inc Azioni (AMGN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.22%
1.18%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):